Clincosm LogoSign in Get a demo

ATG5 as a Serum Marker of Autophagy in Psoriatic Patient

Sponsor
Sohag University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05279638
Collaborator
(none)
90
Enrollment
1
Location
23
Anticipated Duration (Months)
3.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

it will be of interest to know the ATG 5 as a serum marker of autophagy in serum of psoriasis vulgairs patients and explore its relationship with psoriasis severity.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: serum ATG5

Study Design

Study Type:
Observational
Anticipated Enrollment :
90 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Evaluation of ATG5 as Aserum Marker of Autophgy in Psoriasis Vulgaris Patients
Actual Study Start Date :
Feb 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2023
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
psoriasis vulgaris patients

psoriasis vulgaris patients , both sex , 18,55 years old

Diagnostic Test: serum ATG5
This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
Other Names:
  • human autophgy protien 5 ELISA kit

    		•
    healthy participants

    Diagnostic Test: serum ATG5
    This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
    Other Names:
  • human autophgy protien 5 ELISA kit

    		•

    Outcome Measures

    Primary Outcome Measures

    1. serum level of ATG5 in psoriatic patients [Within 6 months]

      evaluation of serum ATG5 in psoriasis vulgaris patients by ELISA

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    Psoriasis vulgaris of both sex, age 18-55 years

    Exclusion Criteria:
    1. Patients with other types of psoriasis ii. Pregnant or lactating women iii. patients with hepatic or renal diseases iv. patients receive any systemic treatment in last 3 months

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sohag University Sohag Egypt

    Sponsors and Collaborators

    • Sohag University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ayatallah Hamdy Abdelrahim, Resident physician, Sohag University
    ClinicalTrials.gov Identifier:
    NCT05279638
    Other Study ID Numbers:
    • Soh-Med-22-02-03
    First Posted:
    Mar 15, 2022
    Last Update Posted:
    Mar 15, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ayatallah Hamdy Abdelrahim, Resident physician, Sohag University
    serum marker
    ATG5
    Additional relevant MeSH terms:
    Psoriasis

    Study Results

    No Results Posted as of Mar 15, 2022